David A. Siegel Beam Therapeutics Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 19,000 shares of BEAM stock, worth $615,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,000
Previous 10,700
77.57%
Holding current value
$615,600
Previous $262,000
79.77%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BEAM
# of Institutions
248Shares Held
77.8MCall Options Held
407KPut Options Held
123K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$267 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$247 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$247 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$229 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$147 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $2.28B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...